International Forum of Allergy & Rhinology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2024-08-23 ms7000001893832347 来自湖北省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：meta分析及综述;临床
经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线：
Received: 9 March 2023
Revised: 14 July 2023
Accepted: 14 August 2023

59 0

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2024-07-24 ms4000002063543822 来自广东省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：过敏
经验分享：三天UR，十几天Rejected

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2017-12-04 sanming1978

审稿速度:1.0 | 投稿命中率:50.0
经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%

424 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2022-04-02 我是大王啊

投稿命中率:5.0
经验分享：看上去比较难

142 0

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2021-12-29 rayms

是否需要在讨论中说明文章局限性？

136 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2021-12-28 MS68862005

文章的局限性是什么？

149 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2019-11-06 sanming1978

审稿速度:1.0 | 投稿命中率:25.0
经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。

247 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222170, encodeId=0ed922221e0ac, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：meta分析及综述;临床 经验分享：这个杂志较为小众，找了很久才找到跟文章主题极其契合的杂志。返修共两次，审稿人阅读较为仔细。贴出时间线： Received: 9 March 2023 Revised: 14 July 2023 Accepted: 14 August 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bb8189804, createdName=ms7000001893832347, createdTime=Fri Aug 23 22:42:28 CST 2024, time=2024-08-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2216599, encodeId=584b221659900, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：过敏 经验分享：三天UR，十几天Rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1f79369769, createdName=ms4000002063543822, createdTime=Wed Jul 24 11:26:47 CST 2024, time=2024-07-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=549700, encodeId=3a34549e00ca, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇稿子，临床研究，鼻窦CT解剖的内容，审稿时间1个月，就快有结果了。祈祷。杂志的文章适合临床医生看。查阅每年发稿量200篇左右，投稿量400篇左右。因此命中率该有50%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=424, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Mon Dec 04 12:33:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208079, encodeId=359812080e98c, content=投稿命中率:5.0 经验分享：看上去比较难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/26/36ed576c56d438bd470a048921542ca0.jpg, createdBy=aa382014808, createdName=我是大王啊, createdTime=Sat Apr 02 10:38:46 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105330, encodeId=2c4411053304e, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105329, encodeId=f61f110532996, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579448, encodeId=c93d5e944883, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=677940312, createdName=sanming1978, createdTime=Wed Nov 06 00:00:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584783, encodeId=5af8584e8328, content=你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, beContent=sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=427d5279584, createdName=1483dc91m26(暂无昵称), createdTime=Sat Feb 15 00:00:00 CST 2020, time=2020-02-15, status=1, ipAttribution=)]

2020-02-15 1483dc91m26(暂无昵称)

你好，稿费大约多少呢sanming1978 2019-11-06 00:00:00 发表:
Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。

sanming1978 2019-11-06 00:00:00 发表: Your manuscript ID is ALR-?19-0667?.?11月5日的稿件。估计年稿件量在8000篇，发稿200篇，接收率该是25%。

204 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务